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Advanced glycation end products (AGEs) react non-enzymatically with tissue proteins to form ir-
reversible structures involved in atherosclerosis, nephropathy, retinopathy, neuropathy, and 
wound healing. Studies on AGE-inhibitors have demonstrated possible prevention of diabetes 
complications. The present open label study was conducted on aminoguanidine (AGu), an inhibi-
tor of AGE-formation, to examine potential effects on wound healing in diabetes type 2-like db/db 
mice during 5 - 6 weeks. The animals were divided into 4 groups: AGu from the day of wounding 
(day 0) topically and/or systemically in drinking water (1 g/L; group 1, n = 13); AGu 1 g/L in 
drinking water from 7 weeks prior to day 0 (group 2, n = 21); AGu 5 g/L in drinking water from 9 - 
11 weeks prior to day 0 (group 3, n = 6); placebo controls (group 4, n = 8). Results: Glycated he-
moglobin (A1C) was significantly lower in group 3 compared to the other groups (P < 0.05). Per-
centage change in A1C and body weight from baseline to the end of the experiment were both re-
lated to the AGu doses (1 or 5 g/L; A1C-change, P = 0.01; weight-change, P = 0.04, both for linear 
trend across groups 4, 2, and 3, respectively). Even so, percentage wound closure was not im-
proved in the AGu-treated groups compared to controls (P ≥ 0.8). 
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tissue proteins [1]. Studies have demonstrated that AGE-formation is implicated both in micro- and macrovas-
cular complications such as atherosclerosis, nephropathy, retinopathy, neuropathy, and wound healing [2]-[7].  
Several studies have been performed on the effects of AGE inhibition since 1986 when a report on the proto-
type AGE inhibitor—aminoguanidine—was published [1] [8]. This is a scavenger of reactive carbonyl interme-
diates in the Maillard reaction in which AGEs are formed non-enzymatically [1]. In a phase III clinical trial 
aminoguanidine (AGu) demonstrated reduced proteinuria and diminished progression of retinopathy [9].  
The AGE inhibitors thiamine and pyridoxine both improved endothelial cell migration in bovine and human 
cell cultures [10] [11]. Furthermore, benfotiamine, a diacylglycerol-protein kinase C (PKC)- and AGE inhibitor, 
has been shown to protect against necrosis in ischemic limbs in type 1 diabetic mice [12].  
Interference with the receptor for AGE (RAGE) by using soluble RAGE (sRAGE) or a neutralizing RAGE 
antibody is another principle of intervening on the action of AGEs [7] [13]. In an experiment with sRAGE 
wound healing was improved in type 2-like diabetic (db/db) mice [7]. Furthermore, AGE inhibition with ami-
noguanidine seems to improve wound healing in type 1 diabetic rats [14] [15]. 
The effect of AGE inhibition on wound healing has never been assessed in the diabetic db/db mouse model 
that is the most widely used animal model for type 2 diabetes [16] [17]. The present study was therefore con-
ducted to investigate the potential effects of aminoguanidine on wound healing in this strain of mice.  
2. Materials and Methods 
2.1. Animals 
Diabetic C57Bl/KsBom-db/db mice were studied. All animals were purchased from M & B A/S, Ry, Denmark. 
The db/db strain is a well-recognized model for type 2 diabetes mellitus in which the diabetic state results from a 
deficient leptin receptor associated with an autosomal recessive mutation in the db-gene on chromosome four 
encoding this receptor [18]. The animals become obese, insulin resistant, and hyperinsulinemic. After the age of 
2 - 3 months atrophy of pancreatic islets causes severe hyperglycemia [16]. 
The animals were housed under the same conditions as previously reported, including rodent food, SDS RM 1 
(E), (Special Diets Services, Essex, England) and water ad libitum [19]. Body weight was measured weekly 
(Mettler PM 2000, Mettler Instrument Corp., Hightstown, NJ, USA). The Norwegian Ethics Committee for Re-
search on Animals approved the experimental protocols. 
Forty-eight animals (26 females) were studied. From the age of 4 - 7 weeks 27 mice were given aminoguani-
dine (AGu) in the drinking water in concentrations of 1 g/L (n = 21) or 5 g/L (n = 6). The concentrations were 
based on previous studies [20].  
2.2. Anesthesia and Blood Sampling 
General anesthesia was introduced after four hours of fasting (but still with water ad libitum). A mixture of fen-
tanyl/fluanisone and midazolam (final concentrations 0.079 mg/mL fentanyl, 2.50 mg/mL fluanisone, and 1.25 
mg/mL midazolam; dose: 0.0075 mL/g body weight) was administered subcutaneously. Blood samples were 
drawn from the large saphenous vein on anesthetized animals, placed in heparinized tubes, stored in ice for ap-
proximately one hour until the measurements of fasting plasma glucose (fPG), plasma lactate (p-lactate), and 
glycated hemoglobin (A1C).  
2.3. Wounding 
We used the same excisional model as previously reported, which is a modification of the procedure described 
by Greenhalgh et al. [19] [21]. In brief, the procedure was performed on anesthetized animals, aged 11 - 18 
weeks, having the mid-part of their back shaved, chemically depilated using Nair cream (Carter-Wallace Ltd., 
Folkestone, Kent, England), and washed with tap water. A template was used to mark a 1.5 × 1.5 cm2 area on 
the skin.The depilated area was disinfected with chlorhexidine 5 mg/mL prepared at the hospital pharmacy and 
washed with sterile water. A full-thickness skin wound was made on the back of the mice by excising the skin 
and panniculus carnosus under optimal clean conditions. The wound was thereafter covered with a semi-permeable, 
transparent polyurethane dressing, OpsiteFlexigrid (Smith & Nephew Medical Ltd., Hull, England), that was 
fixed with the tissue adhesive, enbucrilate (Histoacryl, B. Braun Melsungen AG, Melsungen, Germany), and 
5-0 Monosof sutures (Auto Suture Company, Norwalk, CT, USA). The wound margins were finally traced 




onto glass microscope slides (=area day 0), and buprenorphine was given subcutaneously as analgesia (final 
concentration 0.030 mg/mL buprenorphine; dose: 0.007 mL/g body wt). Another dose of buprenorphine was 
given twelve hours after wounding. Furthermore, an isotonic electrolyte solution, Ringer Acetate (Fresenius 
Kabi Norge AS, Halden, Norway), was given subcutaneously zero and two hours after the surgical procedure. 
The following four groups were studied, and the observation period was up to 45 days: 
1) N = 13 mice were given topical AGu [final concentration 50 mg/mL in NaCl 9 mg/mL (Fresenius Kabi— 
Norge AS, Halden, Norway)] at the day of wounding (day 0) with (n = 8) or without (n = 5) additional AGu in 
the drinking water (final concentration 1 g/L) from day 0. 
2) In order to examine long-term AGu-effects n = 21 mice received prewounding intervention with AGu in the 
drinking water (final concentration 1 g/L) from the age of 4 - 6 weeks. 
3) Long-term- and high-dose effects were studied in n = 6 mice that had prewounding intervention with AGu in 
the drinking water (final concentration 5 g/L) from the age of 5 - 7 weeks.  
4) N = 8 placebo control animals were given tap water and topically applied 100 µl of NaCl 9 mg/mL onto the 
wound once daily for five consecutive days from surgery. 
No animals in group 1 had prewounding AGu treatment. Since the two subgroups with or without AGu in the 
drinking water were similar with respect to all variables measured (for all comparisons, P > 0.1; repeated mea-
surements analysis of variance for percentage wound closure and t-tests for the remaining variables), they were 
pooled and analyzed together. 
Ten out of sixty-five mice (15.4%) died after wounding from unknown reasons and were therefore not in-
cluded in the analysis. The difference between groups 1 - 4 in terms of post-surgery deaths was not significant, 
group 1: 5 in 19 (26%); group 2: 2 in 29 (7%); group 3: 3 in 9 (33%); group 4: 0 in 8 (0%); P = 1.0, 
Kruskal-Wallis test. Another 7 mice (13%) were excluded because of wound infection.  
The conditions of the animals during the experiments and the procedures performed at the end of the study 
period were as previously reported [19]. 
The choice of topically applied AGu at a final concentration of 50 mg/mL (406 mM) was significantly higher 
compared to what was used in a previous study [22]. However, since we only gave one dose (10 mg) this was 
considered appropriate. 
Our previous studies on wound healing gave identical placebo results with or without topical applications of 
NaCl 9 mg/mL [23]. We therefore chose not to give additional topical placebo wound treatment in the groups 
with systemic AGu supply (groups 1 - 3). 
All experiments were performed within a time frame of 24 months, and results from group 4 have previously 
been presented [24]. 
2.4. Preparation and Application of Aminoguanidine 
Topical treatment with AGu was performed by injecting the solution of AGu hemisulfate (Sigma-Aldrich, St. 
Louis, MO, USA) in NaCl 9 mg/mL onto the wound in the same manner as previously reported on aminated 
β-1,3-D-glucan [19]. 
2.5. Wound Closure Measurement 
The measurements were performed at 7 different time points over 17 days as previously reported [19]. Percent-
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The measurements were performed by computerized planimetry using Adobe Acrobat 7.0 Professional 
(Adobe Systems Inc., San José, CA, USA) as previously described [24].  
2.6. Metabolic Parameters 
Fasting plasma glucose and lactate measurements were performed with the YSI Glucose and L-Lactate Analyzer 
Model 2300-GL STAT (Yellow Springs Instrument Co., Yellow Springs, OH, USA). A1C was analysed using the 
DCA 2000 + Analyzer Model 5031 C (Bayer Corporation, Elkhart, IN, USA). The analyses were performed 




according to the manufacturers’ guidelines. 
The points in time for the measurements of fPG and baseline body weight (wtday7), day 0 before wounding and 
the postoperative day 7, respectively, were both chosen to avoid effects of potential stress reactions associated 
with the wounding. 
2.7. Bacteriological Examination and Fungus Cultivation 
Samples were harvested from wound bed abradant on anesthetized animals at the end of the experimental period. 
Animals with signs of a wound infection (green-yellowish secretion and decreased closure rate) and/or growth 
of wound pathogens (e.g., Staphylococcus aureus) were excluded from the study. 
Among 55 mice 7 (13%) were excluded based on signs of wound infection. The occurrence of infections in 
groups 1 - 4 [1 in 14 (7%), 6 in 27 (22%), 0 in 6 (0%), and 0 in 8 (0%), respectively] was not significantly dif-
ferent between the groups (P = 1.0, Kruskal-Wallis test). Specimens for bacterial growth were taken from 4 of 
these wounds, and abundant growth of bacteria was detected (samples 1 - 4): 1. Staphylococcus aureus and En-
terococci, 2. and 3. Staphylococcus aureus, and 4. Escherichia coli. 
2.8. Statistical Analysis 
The distributions of all variables were evaluated by visual inspection of frequency histograms. All data were 
normally distributed and are presented as mean ± standard error of the mean (SE). Statistical significance be-
tween groups was tested by t-tests and one-way analysis of variance (oneway ANOVA). Univariate ANOVAs 
were applied for the testing of potential linear trends across groups. The data on percentage wound closure be-
tween days 0 and day 17 were analyzed by repeated measurements ANOVA, and Bonferroni correction was ap-
plied for multiple comparisons when appropriate.  
Analysis was performed by the statistical package IBM SPSS Statistics for Windows, version 21.0 (IBM 
Corp., Armonk, NY, USA). P < 0.05 (two-tailed) was considered as statistically significant. 
3. Results 
Wound Healing and Characteristics of the Experimental Animals 
Plasma glucose levels in the four intervention groups were similar at wounding (day 0; P > 0.2 for all compari-
sons, Table 1). Aminoguanidine treatment from day 0 (group 1), or from 7 weeks before day 0 (group 2) did not 
improve wound healing compared to placebo (group 4), P = 1.0 for both comparisons (Figure 1). Wound clo-
sure in the long-term and higher-(AGu) dose group (group 3) tended to be less versus placebo, however mean 
difference was not significant (−9.1% ± 5.9%, P = 0.8, Figure 1). 
At the time of wounding (day 0) all animals were obese and polyuric, both characteristics consistent with di-
abetes. Furthermore, the characteristics of the four intervention groups were similar at baseline, except for group 
3 that was significantly older (Table 1). 
At follow-up groups 1, 2, and 4 significantly lost body weight (Table 1, all P ≤ 0.008, paired-samples t-tests) 
while group 3 did not (P = 0.7). Moreover, fasting plasma glucose did not change in any group during experi-
ments (P > 0.7), whereas A1C increased slightly in the control group (group 4) (Table 1, P = 0.03). A1C at fol-
low-up was significantly lower in group 3 compared to the three other groups (Table 1).  
The percentage changes in body weight and A1C from baseline to the end of the experiment were both AGu 
dose-related (Figure 2). The corresponding change in fPG however, was not (data not shown). 
4. Discussion 
The aim of our experiments was to study the potential effects of systemic and/or topical administration of ami-
noguanidine in a wound model in diabetic db/db mice. AGu did not significantly improve wound healing, re-
gardless of different systemic doses (1 g/L, 5 g/L) and pretreatment up to 11 weeks before wounding (groups 2 
and 3).  
To our knowledge, there are no other studies in the db/db- or other diabetic mouse models on wound healing 
associated with the use of AGu. However, in type 1 diabetic rats AGu demonstrated beneficial effects in wound 
healing and skin flap survival [14] [15]. AGu-treatment in nondiabetic mouse models has been associated with  




Table 1. Characteristics of the experimental animals.                                                             
Intervention group (n) 
1 2 3 4 
AGu, topical 50 g/L + 
systemic 1 g/L (13) 
Systemic AGu 1 g/L 
(21)† 




Start of intervention day 0 7 weeks prior to day 0 
9 - 11 weeks 
prior to day 0 (untreated) 
Time of observation baseline end baseline end baseline end baseline end 
Age (weeks) 
(baseline at day 0) 11.5 - 14 16 - 20 11 - 13 15 - 20 14 - 18 20 - 24 12 - 13 16 - 20 
Body weight (g) 
(baseline at day 7) 35.7 ± 1.3 32.3 ± 1.6 39.5 ± 0.7 35.4 ± 1.4 36.8 ± 1.5 36.0 ± 2.5 35.8 ± 1.6 31.1 ± 2.3 
fPG(mmol/L) 
(baseline at day 0) 29.3 ± 1.8 29.1 ± 2.3 27.0 ± 1.8 27.6 ± 1.8 20.3 ± 3.4 19.5 ± 4.8 28.7 ± 3.9 28.6 ± 3.6 
A1C (%) 
(baseline at day 0) - - 11.9 ± 0.6 12.4 ± 0.8 9.5 ± 0.7 8.4 ± 1.0 11.8 ± 1.1 13.1 ± 0.9 
p-lactate (mmol/L) 
(baseline at day 0)  1.8 ± 0.2 2.2 ± 0.2 1.6 ± 0.1 2.2 ± 0.2 2.1 ± 0.1 2.5 ± 0.3 1.8 ± 0.1 1.8 ± 0.3 
Data are mean ± SE. Baseline observations were performed at day 0 (the day of wounding) for all variables except from body weight that was meas-
ured at day 7 to avoid effects of potential stress reactions associated with the wounding. Group 3 was significantly older than the three other groups (P 
< 0.0005). The remaining baseline characteristics were similar across the intervention groups, for all comparisons P > 0.1 (one way analysis of variance 
(ANOVA), Bonferroni correction for multiple comparisons). In follow-up A1C was significantly lower in group 3 (P = 0.040 versus placebo (group 4), 
and P = 0.048 versus group 2; repeated measurements ANOVA). †n = 13 for the A1C-measurements, and blood sampling was unsuccessful in fol-
low-up in one animal. AGu, aminoguanidine; fPG, fasting plasma glucose; A1C, glycated hemoglobin; - analysis not performed. 
 
 
Figure 1. Wound closure in groups 1 (n = 13) and 2 (n = 21) was not significantly different from placebo controls (n = 8; 
both P = 1.0, repeated measurements analysis of variance). In group 3 (n = 6) wounds tended to close less versus placebo, 
however not significant (P = 0.8). Data are mean ± SE.                                                          
 
 
Figure 2. Dose-related percentage change (∆) of body weight and glycated hemoglobin (A1C), both from baseline to the end 
of experiment, after treatment with aminoguanidine (AGu) 1 g/L or 5 g/L for 12 - 17 weeks. Significant linear trends were 
detected across groups (placebo, n = 8; AGu 1 g/L*, n = 21; AGu 5 g/L, n = 6, respectively) for dose-related percentage 
change (∆ body weight, P = 0.04; ∆ A1C, P = 0.01, univariate analysis of variance). *n = 13 for the A1C-measurements. 
Data are mean ± SE.                                                                                      




effects that are not in accordance with each other. One study on intra-peritoneal AGu administration in young (8 
- 9 weeks) animals showed decreased collagen accumulation, and another on topical AGu application in young 
(10 - 12 weeks) and old (>52 weeks) mice reported increased wound closure [20] [22]. In the present study AGu 
demonstrated putative metabolic effects since A1C was lower in the high dosage group (group 3) compared to 
controls (group 4). Even so, wound healing was not improved. 
Aminoguanidine is an AGE inhibitor, but also an inhibitor of inducible nitric oxide synthase (iNOS) that is 
implicated in the NO synthesis from arginine by inflammatory cells and fibroblasts [8] [20]. One could therefore 
speculate that lack of NO was implicated in our findings since nitric oxide deficiency at the wound site was re-
ported in diabetes, and the intake of a nitric oxide donor in diabetic rats enhanced wound healing [25]. 
Our findings are apparently contradictory to some previous studies on AGu in rodent wound models [14] [15] 
[22]. First, the effects of AGu on wound healing may be different in diabetic and nondiabetic models, and may 
also rely on strain- and/or species differences [14] [15] [20] [22]. Second, the plasma half-life of aminoguani-
dine is short (∼1 hour), and high AGu concentrations are required to continuously react with and trap AGEs [1]. 
However, a typical high dose is 1 g/L in drinking water as used in the present study (equivalent to ∼1 g/kg/d), 
and we included a five times higher dose as well [1]. In type 1 diabetic rats 1 g/L of AGu in the drinking water 
improved wound repair, and skin flap necrosis was prevented using intraperitoneal injections of AGu 100 
mg/kg/day [14] [15]. In nondiabetic mice the administration of AGu 1 g/L in the drinking water had no effect on 
the concentrations of the stable end products of NO, nitrite and nitrate, or collagen accumulation in wounds, 
while AGu 500 mg/kg/day given continuously through intra-peritoneal osmotic pumps decreased the wound 
fluid nitrite/nitrate concentrations and the accumulation of collagen [20]. Third, the duration of treatment in our 
model (12 - 17 weeks) may have been inappropriately short to achieve an effect on wound healing. However, 
beneficial effects and improved wound healing have been achieved after 6-7 days of treatment in different type 1 
diabetic rat models, and collagen accumulation decreased in non-diabetic mice after 10 days of intraperitoneal 
AGu administration [14] [15] [20].  
A1C is a reversible glycated protein that has shown a significant correlation with hemoglobin-AGE in humans 
[26]. In our study the largest dose of AGu (group 3) was paralleled by a significantly lower A1C level compared 
to controls, and the percentage change in A1C from baseline to the end of our experiments was related to the 
AGu doses (1 g/L or 5 g/L). Accordingly, weight change from baseline to the end of the experiments in these 
groups was AGu dose-related. These findings are consistent with an antidiabetic effect in the db/db mouse mod-
el [27]. Since there is no published evidence that AGu traps AGE precursors in vivo, our results can potentially 
be explained by less advanced glycation of the islets of Langerhans and less islet atrophy [1] [26] [28].  
Strengths of the present study include first, examination of different AGu doses (1 g/L, 5 g/L) and their ef-
fects. Second, the experiments were conducted in a well-recognized animal model of type 2-diabetes and wound 
healing [7] [21] [24]. Third, metabolic effects (body weight, A1C) associated with the relatively long lasting in-
tervention were detected and accounted for.  
Limitations are, first, that the intake of food and water was not measured, and the urine output was not moni-
tored. Second, A1C was not measured in all animals. Third, data on serum- and pancreatic insulin are lacking. 
Fourth, the study lacks measurements in wound tissue, wound fluid, and skin of collagen accumulation (hy-
droxyproline content), AGE deposition, or nitrite/nitrate concentrations.  
5. Conclusion 
In conclusion, aminoguanidine did not improve wound healing in the diabetic db/db mouse model. Moreover, 
since aminoguanidine is both an AGE- and an iNOS inhibitor [8] [20], future experiments could be considered 
in order to address counteractive mechanisms opposing the beneficial effect of AGE inhibition. 
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